Company Presentation

We aim to revolutionize hematopoietic stem cell transplantation by improving the conditioning step through enhanced safety, tolerability and efficacy for patients with blood diseases, primarily Acute Myeloid leukemia. Our lead candidate, ALY117, offers an approach to reduce minimal residual disease and to prepare the patient to receive the transplant. With a dedicated team consisting of scientist and doctors plus a strategic focus, we’re poised to make a meaningful impact.